JP2023524206A5 - - Google Patents
Info
- Publication number
- JP2023524206A5 JP2023524206A5 JP2022564519A JP2022564519A JP2023524206A5 JP 2023524206 A5 JP2023524206 A5 JP 2023524206A5 JP 2022564519 A JP2022564519 A JP 2022564519A JP 2022564519 A JP2022564519 A JP 2022564519A JP 2023524206 A5 JP2023524206 A5 JP 2023524206A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- tetrahydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2005863.2 | 2020-04-22 | ||
| GBGB2005863.2A GB202005863D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
| PCT/GB2021/050973 WO2021214470A1 (en) | 2020-04-22 | 2021-04-22 | Tetrahydroisoquinoline compounds as nrf2 activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524206A JP2023524206A (ja) | 2023-06-09 |
| JP2023524206A5 true JP2023524206A5 (enExample) | 2024-05-01 |
| JP7679400B2 JP7679400B2 (ja) | 2025-05-19 |
Family
ID=70860156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564519A Active JP7679400B2 (ja) | 2020-04-22 | 2021-04-22 | Ｎｒｆ２活性化剤としてのテトラヒドロイソキノリン化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230167084A1 (enExample) |
| EP (1) | EP4139294B1 (enExample) |
| JP (1) | JP7679400B2 (enExample) |
| KR (1) | KR20230004720A (enExample) |
| CN (1) | CN115667243B (enExample) |
| AR (1) | AR121912A1 (enExample) |
| AU (1) | AU2021259366A1 (enExample) |
| BR (1) | BR112022021244A2 (enExample) |
| CA (1) | CA3174361A1 (enExample) |
| ES (1) | ES3032247T3 (enExample) |
| GB (1) | GB202005863D0 (enExample) |
| IL (1) | IL297434A (enExample) |
| MX (1) | MX2022013398A (enExample) |
| PH (1) | PH12022552775A1 (enExample) |
| WO (1) | WO2021214470A1 (enExample) |
| ZA (1) | ZA202211465B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64836B1 (sr) * | 2018-10-22 | 2023-12-29 | C4X Discovery Ltd | Terapijska jedinjenja |
| AU2023204960A1 (en) * | 2022-01-07 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Nitrogen-containing heterocyclic compound having nrf2 activation effect |
| TW202604491A (zh) | 2024-05-13 | 2026-02-01 | 瑞典商阿斯特捷利康公司 | 用於療法中之ｋｅａｐ１抑制劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003041641A2 (en) * | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| KR20180017038A (ko) * | 2015-06-15 | 2018-02-20 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| RS64836B1 (sr) * | 2018-10-22 | 2023-12-29 | C4X Discovery Ltd | Terapijska jedinjenja |
-
2020
- 2020-04-22 GB GBGB2005863.2A patent/GB202005863D0/en not_active Ceased
-
2021
- 2021-04-22 ES ES21723350T patent/ES3032247T3/es active Active
- 2021-04-22 MX MX2022013398A patent/MX2022013398A/es unknown
- 2021-04-22 US US17/920,226 patent/US20230167084A1/en active Pending
- 2021-04-22 CA CA3174361A patent/CA3174361A1/en active Pending
- 2021-04-22 KR KR1020227040550A patent/KR20230004720A/ko active Pending
- 2021-04-22 PH PH1/2022/552775A patent/PH12022552775A1/en unknown
- 2021-04-22 EP EP21723350.1A patent/EP4139294B1/en active Active
- 2021-04-22 WO PCT/GB2021/050973 patent/WO2021214470A1/en not_active Ceased
- 2021-04-22 IL IL297434A patent/IL297434A/en unknown
- 2021-04-22 CN CN202180031435.0A patent/CN115667243B/zh active Active
- 2021-04-22 JP JP2022564519A patent/JP7679400B2/ja active Active
- 2021-04-22 AU AU2021259366A patent/AU2021259366A1/en active Pending
- 2021-04-22 BR BR112022021244A patent/BR112022021244A2/pt unknown
- 2021-04-22 AR ARP210101080A patent/AR121912A1/es unknown
-
2022
- 2022-10-19 ZA ZA2022/11465A patent/ZA202211465B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524207A5 (enExample) | ||
| US11912686B2 (en) | LPA receptor antagonists and uses thereof | |
| US12139478B2 (en) | Compounds, compositions and methods | |
| JP2025031810A (ja) | 化合物、組成物、及び、方法 | |
| JP2018517731A5 (enExample) | ||
| US9150568B2 (en) | Compositions and methods for modulating FXR | |
| JP2019089828A (ja) | オータキシン阻害剤としての新規オクタヒドロ−ピロロ［３，４−ｃ］−ピロール誘導体及びそのアナログ | |
| TW202045164A (zh) | 化合物、組合物及方法 | |
| AU2020222080B2 (en) | Hydroxypyridoxazepines as Nrf2 activators | |
| US10150766B2 (en) | P2X7 modulators | |
| JP2018534326A5 (enExample) | ||
| JP2024525900A (ja) | グルカゴン様ペプチド－１受容体モジュレーター及びその使用 | |
| US20130261108A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| JP2019532033A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| JP2018529745A5 (enExample) | ||
| JP2019529443A (ja) | Ｔｒｐｖ４拮抗薬 | |
| JP2018529744A5 (enExample) | ||
| US20230002391A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| JP2010518146A (ja) | ベンゾフラン化合物 | |
| US20230382892A1 (en) | Chemical Compounds | |
| JP2021514984A (ja) | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０−（ジ（フェニル）メチル）−４−ヒドロキシ−８，９，９ａ，１０−テトラヒドロ−７Ｈ−ピロロ［１’，２’：４，５］ピラジノ［１，２−ｂ］ピリダジン−３，５−ジオン誘導体および関連化合物 | |
| JP2022516651A5 (enExample) | ||
| TW201412736A (zh) | 二氮呯酮衍生物 | |
| WO2010106106A1 (en) | 2, 5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators | |
| CA2842566A1 (en) | Pyrazoline derivatives and their use as selective androgen receptor modulators |